JP2024536341A5 - - Google Patents

Info

Publication number
JP2024536341A5
JP2024536341A5 JP2024520543A JP2024520543A JP2024536341A5 JP 2024536341 A5 JP2024536341 A5 JP 2024536341A5 JP 2024520543 A JP2024520543 A JP 2024520543A JP 2024520543 A JP2024520543 A JP 2024520543A JP 2024536341 A5 JP2024536341 A5 JP 2024536341A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
ticagrelor
acid
smedds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024520543A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024536341A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/059429 external-priority patent/WO2023057879A1/en
Publication of JP2024536341A publication Critical patent/JP2024536341A/ja
Publication of JP2024536341A5 publication Critical patent/JP2024536341A5/ja
Pending legal-status Critical Current

Links

JP2024520543A 2021-10-04 2022-10-03 自閉症スペクトラム障害を有する対象を治療するための方法及び製品 Pending JP2024536341A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163251935P 2021-10-04 2021-10-04
US63/251,935 2021-10-04
PCT/IB2022/059429 WO2023057879A1 (en) 2021-10-04 2022-10-03 Methods and products for treating subjects with autism spectrum disorders

Publications (2)

Publication Number Publication Date
JP2024536341A JP2024536341A (ja) 2024-10-04
JP2024536341A5 true JP2024536341A5 (enExample) 2025-01-14

Family

ID=83688729

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024520543A Pending JP2024536341A (ja) 2021-10-04 2022-10-03 自閉症スペクトラム障害を有する対象を治療するための方法及び製品

Country Status (16)

Country Link
US (1) US11878016B2 (enExample)
EP (1) EP4412616A1 (enExample)
JP (1) JP2024536341A (enExample)
KR (1) KR20240089377A (enExample)
CN (1) CN118265521A (enExample)
AU (2) AU2022358998B2 (enExample)
CA (1) CA3232273A1 (enExample)
CL (1) CL2024000992A1 (enExample)
CO (1) CO2024005762A2 (enExample)
CR (1) CR20240184A (enExample)
EC (1) ECSP24033949A (enExample)
IL (1) IL311681B2 (enExample)
MX (1) MX2024004150A (enExample)
PE (1) PE20241338A1 (enExample)
TW (1) TW202322821A (enExample)
WO (1) WO2023057879A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025051399A1 (en) * 2023-09-10 2025-03-13 Dafechem Ltd Liquid ticagrelor formulation
WO2025247961A1 (en) * 2024-05-31 2025-12-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Lpa-lpar signaling as a therapeutic target or diagnostic tool for brain diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2834247A4 (en) * 2012-04-05 2016-03-30 Reddys Lab Ltd Dr PREPARATION OF TICAGRELOR
CN104971042B (zh) 2014-04-04 2018-01-05 中国医学科学院医药生物技术研究所 替格瑞洛口服自微乳组合物
CN104434931A (zh) * 2014-11-06 2015-03-25 南京华威医药科技开发有限公司 含替格瑞洛和阿司匹林的复方口服固体剂及其制备方法
CN105669674A (zh) 2014-11-21 2016-06-15 重庆圣华曦药业股份有限公司 一种替卡格雷新晶型及其在药物制剂中的应用
KR102488486B1 (ko) * 2016-04-21 2023-01-12 아스트라제네카 아베 경구 붕해 정제
CN105943515A (zh) 2016-06-24 2016-09-21 山东鲁抗医药股份有限公司 一种替格瑞洛口腔崩解片及其制备方法
TR201617983A2 (tr) * 2016-12-07 2018-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Ti̇cagrelorun kati oral farmasöti̇k bi̇leşi̇mleri̇
US10614684B2 (en) * 2017-01-31 2020-04-07 The United States Government As Represented By The Treatment of kidney diseases associated with elevated AVP
WO2019084543A1 (en) * 2017-10-27 2019-05-02 Beyond Barriers Therapeutics, Inc. ENHANCED ANTIOXIDANT ADMINISTRATION FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS INVOLVING OXIDATIVE STRESS
KR102007731B1 (ko) 2018-02-12 2019-08-06 충남대학교산학협력단 티카그렐러를 포함하는 자가 미세유화 약물전달시스템 조성물 및 이의 제조방법
CN110876750A (zh) * 2018-09-06 2020-03-13 江苏恒瑞医药股份有限公司 一种含有替格瑞洛或其可药用盐的缓释组合物
EP4157271A1 (en) 2020-05-29 2023-04-05 Boulder Bioscience LLC Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane

Similar Documents

Publication Publication Date Title
CA2663062C (fr) Forme galenique pour l'administration par voie trans-muqueuse de principes actifs
KR102299359B1 (ko) 케타민 경피 전달 시스템
CN102026618B (zh) 多巴胺激动剂的胃肠外制剂
JP2024536341A5 (enExample)
JP2013501718A5 (enExample)
US12128027B2 (en) N—N-dimethyltryptamine (DMT) and DMT analog compositions, methods of making, and methods of use thereof
EP3043777A1 (en) Sublingual buprenorphine spray
JP2002544239A (ja) 抗コリン作用化合物及びβ−擬似剤に基づく新規医薬組成物
CN103889508A (zh) 用于传递丁丙诺啡的防滥用性粘膜粘附剂装置
JP2010518086A (ja) スフェンタニルおよびナロキソンを含む経口腔投与製剤
WO2020086673A1 (en) Ketamine oral transmucosal delivery system
CN101068571A (zh) 改善透粘膜给药制剂的吸收的方法
JP2025509390A5 (enExample)
CA3019769A1 (en) Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
JP2018513869A5 (enExample)
IL311681B1 (en) Methods and products for treating people with autism spectrum disorders
KR20230106658A (ko) 구강용 박막
WO2025076151A1 (en) N-n-dimethyltryptamine (dmt) and dmt analog oral transmucosal film compositions, methods of making, and methods of use thereof
CN1950076A (zh) 含安溴索的局部制剂
CN102958514A (zh) 口腔内崩解片剂
CN103347518A (zh) 含有抗毒蕈碱药物的无推进剂液体制剂
US9839611B2 (en) Sublingual buprenorphine spray
US20080160068A1 (en) Method for a Medicinal Combination Treatment, and Medicament Combinations Suitable Therefor
CN104394865B (zh) 稳定性提高的包含氨氯地平和氯沙坦的组合物
JP2020073583A (ja) ミューオピオイド受容体アンタゴニストとオピオイド剤との組み合わせ剤形